Investigators at the Chinese Academy of Sciences have generated a chimeric monkey by injecting an embryonic stem cell into the morula, which is an extremely early embryo consisting of 16 to 32 cells. The animal survived for only 10 days, and it is not the first live birth of a chimeric primate. But it is the first such chimera with contributions from an embryonic stem cell, and that stem cell contributed a far higher proportion of cells in the newborn than have been achieved in previous attempts at creating chimeras.
New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Abcellera, Affimed, Alligator, Allogene, Ankyra, Calidi, Candel, CDR-Live, Hotspot, Scopus.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers have been reported in a Bristol Myers Squibb Co. patent as potentially useful for the treatment of cancer.
Prism Biolab Co. Ltd. has identified new 7-membered ring-fused compounds acting as Notch signaling inhibitors and reported to be potentially useful for the treatment of neuronal injury and neurodegenerative diseases.
Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the treatment of CD70-expressing cancers.
Grace Science LLC has received FDA clearance of its IND application for GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 deficiency.
IKZF2 encodes the critical zinc fingers 2 and 3, which are responsible for the DNA binding activity of Helios. Researchers from the University of British Columbia and affiliated organizations have identified new de novo dominant negative variants of the IKZF2 gene.
RSS
